Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to investigate the long-term safety and tolerability of SIAC. This is done by comparing SIAC to insulin detemir after 52 weeks of treatment (26 weeks of treatment in trial NN5401-3594 plus 26 weeks of treatment in this extension trial) in terms of the following safety assessments from which endpoints will be calculated: • Adverse events • Hypoglycaemic episodes • Clinical evaluations • Central laboratory assessments including lipid profiles and insulin antibodies • Body weight • Insulin dose
Critère d'inclusion
- Type 1 Diabetes